News


All series


All News

In a Targeted Oncology case-based peer perspectives live discussion with a group of physicians, Corey J. Langer, MD, reviewed the potential for treatment with immunotherapy following chemoradiotherapy for patients with stage III non–small cell lung cancer. Langer discussed these options based off of a case scenario of a patient with stage IIIA lung adenocarcinoma.

TAS-102 improved overall survival in patients with metastatic gastric/gastroesophageal junction cancer, regardless of prior gastrectomy, according to a preplanned subgroup analysis from the phase III TAGS trial published in&nbsp;<em>JAMA Oncology</em>.<br /> &nbsp;

Ruxolitinib demonstrated a significant improvement in overall response rate over best available therapy at day 28 in patients with steroid-refractory acute graft-versus-host disease, according to topline results from the phase III REACH2 trial.&nbsp;Novartis, the company developing the JAK inhibitor, announced in a press release that this met the primary endpoint of the trial.

Patients with treatment-na&iuml;ve EGFR-mutant non&ndash;small cell lung cancer experienced a statistically significant and clinically meaningful improvement in progression-free survival with the combination of ramucirumab and erlotinib compared with erlotinib alone, according to the results of the phase III RELAY trial which was recently published in The Lancet Oncology.

In a presentation at the 2019 ESMO Congress on a case series of 7 pretreated patients with <em>NRG1</em>-positive tumors, Stephen Liu, MD, and colleagues discussed the efficacy of afatinib and explained that afatinib may be a potential treatment option for <em>NRG1</em>-positive tumors across multiple cancer types.

In an interview with <em>Targeted Oncology</em>, Kasi, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the University of Iowa, Holden Comprehensive Cancer Center, discussed the current role and utility of liquid biopsy in colorectal cancer, and what he&rsquo;s looking forward to bringing up during the 2019 ISGIO Annual Conference.

Multiple presentations at the 2019 ESMO Congress add to the evidence that blood-based biomarkers have predictive utility in advanced non-small cell lung cancer. Blood-based next-generation sequencing has also shown clinical utility in aiding treatment decisions for physicians treating this disease.

In the phase III INVICTUS trial, ripretinib, a novel KIT and PDGFRA inhibitor, demonstrated a dramatic improvement in progression-free survival compared with placebo in heavily pretreated patients with heavily advanced gastrointestinal stromal tumors, according to data presented at the 2019 ESMO Congress.

The multikinase inhibitor entrectinib induced frequent and durable responses, which often deepened over time, in patients with <em>ROS1</em>-positive and&nbsp;<em>NTRK</em>-positive non&ndash;small cell lung cancer, according to an integrated analysis of 3 clinical trials.

In the phase III CASPIAN study, durvalumab added to etoposide and platinum-based chemotherapy delayed the development of new lesions and improved patient-reported outcomes compared to etoposide and platinum-based therapy alone in untreated patients with extensive-stage small cell lung cancer.

Patients with high-grade serous ovarian cancer experienced a 32% reduction in the risk of progression or death with frontline combination veliparib plus carboplatin and paclitaxel followed by veliparib maintenance, according to the data from the phase III VELIA trial presented at the 2019 ESMO Congress, and simultaneously published in the&nbsp;New England Journal of Medicine.